We systematically analyzed the distribution of HER2 amplification and clinicopathological features across various subtypes of cervical adenocarcinomas using IECC, a new pathogenetic classification for invasive endocervical adenocarcinoma [5]. This evidence concerns the gene ERBB2 and cervical adenocarcinoma.